# SCN2A

## Overview
The SCN2A gene encodes the sodium voltage-gated channel alpha subunit 2, known as NaV1.2, which is a critical component of the voltage-gated sodium channel family. This transmembrane protein plays a pivotal role in the initiation and propagation of action potentials in neurons, particularly within the central nervous system (Que2021Hyperexcitability; Sanders2018Progress). NaV1.2 is predominantly expressed in excitatory neurons, such as those in the cortex and hippocampus, and is essential for neuronal excitability and communication (Sanders2018Progress). The channel's structure, characterized by four homologous domains with six transmembrane segments each, facilitates its function in the rapid transmission of electrical signals by allowing sodium ions to enter the cell during the depolarization phase of the action potential (Sanders2018Progress; Hedrich2019SCN2A). Mutations in SCN2A are associated with a spectrum of neurological disorders, underscoring its clinical significance in neurodevelopmental and epileptic conditions (Richardson2021Further; Wolff2017Genetic).

## Structure
The SCN2A gene encodes the NaV1.2 sodium channel, a pseudo-heterotetrameric protein structure composed of four homologous domains (I-IV), each containing six transmembrane segments (S1-S6) (Sanders2018Progress). The S1-S4 segments form the voltage-sensing domains, with the S4 segment acting as the voltage sensor, while the S5-S6 segments form the pore loops and the DEKA-selectivity filter, which is crucial for ion selectivity (Sanders2018Progress; Hedrich2019SCN2A). 

The NaV1.2 channel undergoes conformational changes during activation, inactivation, and recovery from inactivation, processes that are influenced by the specific amino acid sequence and structure of the channel (Hedrich2019SCN2A). The channel's structure is stabilized by interactions with proteins such as Ankyrin G and calmodulin, which may play regulatory roles (Sanders2018Progress).

SCN2A has two known splice isoforms, 5N and 5A, which differ by a single amino acid at position 209. These isoforms are developmentally regulated, with the 5N isoform co-expressed with 5A in the fetal brain, transitioning to predominantly 5A expression in adult neurons (Sanders2018Progress). The adult 5A isoform activates at more hyperpolarized voltages, influencing neuronal excitability (Sanders2018Progress).

## Function
The SCN2A gene encodes the alpha-subunit of the voltage-gated sodium channel Nav1.2, which is crucial for the initiation and propagation of action potentials in neurons. This channel is predominantly expressed in excitatory neurons of the central nervous system, including the cortex and hippocampus, and plays a significant role in neuronal excitability and communication (Que2021Hyperexcitability; Sanders2018Progress). Nav1.2 channels are involved in the depolarization phase of the action potential, allowing sodium ions to enter the cell, which is essential for the rapid transmission of electrical signals in the brain (Sanders2018Progress).

In healthy human cells, Nav1.2 is primarily active in the axon initial segment (AIS) of excitatory pyramidal cells, where it initiates action potentials. During early development, Nav1.2 is the main sodium channel isoform in the AIS, but as development progresses, it is largely replaced by Nav1.6 in the distal AIS, while Nav1.2 remains in the proximal AIS to help backpropagate action potentials into the somatodendritic compartment (Sanders2018Progress). This backpropagation can influence various neuronal functions, including gene transcription and synaptic plasticity, which are crucial for normal brain function and development (Sanders2018Progress).

## Clinical Significance
Mutations in the SCN2A gene, which encodes the voltage-gated sodium channel Na v 1.2, are linked to a variety of neurological and neurodevelopmental disorders. These include developmental and epileptic encephalopathies (DEE), autism spectrum disorder (ASD), intellectual disability (ID), and schizophrenia (Richardson2021Further; Sanders2018Progress). The phenotypic spectrum of SCN2A-related disorders is broad, with conditions ranging from benign familial neonatal-infantile seizures (BFNIS) to severe epileptic encephalopathies like Ohtahara syndrome and Dravet syndrome (Reynolds2020The; Wolff2017Genetic).

The nature of the mutation often determines the clinical outcome. Gain-of-function mutations are typically associated with early-onset epilepsies and respond well to sodium channel blockers (SCBs), while loss-of-function mutations are linked to later-onset epilepsy, ASD, and ID, often showing poor response to SCBs (Lauxmann2018Relationship; Wolff2017Genetic). Some SCN2A mutations are de novo, while others are inherited, with gonadal mosaicism also reported (Richardson2021Further).

The phenotypic variability observed in SCN2A-related disorders suggests that other genetic or environmental factors may influence clinical presentation, highlighting the complexity of these conditions (Wolff2017Genetic).

## Interactions
The SCN2A gene encodes the NaV1.2 sodium channel, which is involved in various protein interactions that influence its function and neuronal excitability. NaV1.2 interacts with the beta subunit, such as SCN1B, which modulates its activity and affects the channel's biophysical properties (Sanders2018Progress). The channel also interacts with calmodulin, a calcium-binding messenger protein that can modulate the channel's activity, impacting neuronal excitability and signal transmission (Sanders2018Progress). 

Additionally, NaV1.2 is part of a complex network of interactions with fibroblast growth factor homologous factors and other auxiliary proteins, which further modulate its activity and contribute to the channel's role in the central nervous system (Sanders2018Progress). These interactions are crucial for the proper functioning of NaV1.2, as they can alter the channel's biophysical properties, particularly in regions critical for voltage sensing or ion flux (Sanders2018Progress). Understanding these interactions is essential for comprehending the functional implications of SCN2A variants and their potential role in neurodevelopmental disorders.


## References


[1. (Lauxmann2018Relationship) Stephan Lauxmann, Nienke E. Verbeek, Yuanyuan Liu, Mariana Zaichuk, Stephan Müller, Johannes R. Lemke, Marjan J.A. van Kempen, Holger Lerche, and Ulrike B.S. Hedrich. Relationship of electrophysiological dysfunction and clinical severity inscn2a-related epilepsies. Human Mutation, 39(12):1942–1956, September 2018. URL: http://dx.doi.org/10.1002/humu.23619, doi:10.1002/humu.23619. This article has 29 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.23619)

[2. (Sanders2018Progress) Stephan J. Sanders, Arthur J. Campbell, Jeffrey R. Cottrell, Rikke S. Moller, Florence F. Wagner, Angie L. Auldridge, Raphael A. Bernier, William A. Catterall, Wendy K. Chung, James R. Empfield, Alfred L. George, Joerg F. Hipp, Omar Khwaja, Evangelos Kiskinis, Dennis Lal, Dheeraj Malhotra, John J. Millichap, Thomas S. Otis, Steven Petrou, Geoffrey Pitt, Leah F. Schust, Cora M. Taylor, Jennifer Tjernagel, John E. Spiro, and Kevin J. Bender. Progress in understanding and treating scn2a-mediated disorders. Trends in Neurosciences, 41(7):442–456, July 2018. URL: http://dx.doi.org/10.1016/j.tins.2018.03.011, doi:10.1016/j.tins.2018.03.011. This article has 227 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.tins.2018.03.011)

[3. (Wolff2017Genetic) Markus Wolff, Katrine M. Johannesen, Ulrike B. S. Hedrich, Silvia Masnada, Guido Rubboli, Elena Gardella, Gaetan Lesca, Dorothée Ville, Mathieu Milh, Laurent Villard, Alexandra Afenjar, Sandra Chantot-Bastaraud, Cyril Mignot, Caroline Lardennois, Caroline Nava, Niklas Schwarz, Marion Gérard, Laurence Perrin, Diane Doummar, Stéphane Auvin, Maria J. Miranda, Maja Hempel, Eva Brilstra, Nine Knoers, Nienke Verbeek, Marjan van Kempen, Kees P. Braun, Grazia Mancini, Saskia Biskup, Konstanze Hörtnagel, Miriam Döcker, Thomas Bast, Tobias Loddenkemper, Lily Wong-Kisiel, Friedrich M. Baumeister, Walid Fazeli, Pasquale Striano, Robertino Dilena, Elena Fontana, Federico Zara, Gerhard Kurlemann, Joerg Klepper, Jess G. Thoene, Daniel H. Arndt, Nicolas Deconinck, Thomas Schmitt-Mechelke, Oliver Maier, Hiltrud Muhle, Beverly Wical, Claudio Finetti, Reinhard Brückner, Joachim Pietz, Günther Golla, Dinesh Jillella, Karen M. Linnet, Perrine Charles, Ute Moog, Eve Õiglane-Shlik, John F. Mantovani, Kristen Park, Marie Deprez, Damien Lederer, Sandrine Mary, Emmanuel Scalais, Laila Selim, Rudy Van Coster, Lieven Lagae, Marina Nikanorova, Helle Hjalgrim, G. Christoph Korenke, Marina Trivisano, Nicola Specchio, Berten Ceulemans, Thomas Dorn, Katherine L. Helbig, Katia Hardies, Hannah Stamberger, Peter de Jonghe, Sarah Weckhuysen, Johannes R. Lemke, Ingeborg Krägeloh-Mann, Ingo Helbig, Gerhard Kluger, Holger Lerche, and Rikke S Møller. Genetic and phenotypic heterogeneity suggest therapeutic implications in scn2a-related disorders. Brain, 140(5):1316–1336, April 2017. URL: http://dx.doi.org/10.1093/brain/awx054, doi:10.1093/brain/awx054. This article has 433 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/brain/awx054)

[4. (Que2021Hyperexcitability) Zhefu Que, Maria I. Olivero-Acosta, Jingliang Zhang, Muriel Eaton, Anke M. Tukker, Xiaoling Chen, Jiaxiang Wu, Junkai Xie, Tiange Xiao, Kyle Wettschurack, Layan Yunis, J. Marshall Shafer, James A. Schaber, Jean-Christophe Rochet, Aaron B. Bowman, Chongli Yuan, Zhuo Huang, Chang-Deng Hu, Darci J. Trader, William C. Skarnes, and Yang Yang. Hyperexcitability and pharmacological responsiveness of cortical neurons derived from human ipscs carrying epilepsy-associated sodium channel nav1.2-l1342p genetic variant. The Journal of Neuroscience, 41(49):10194–10208, October 2021. URL: http://dx.doi.org/10.1523/jneurosci.0564-21.2021, doi:10.1523/jneurosci.0564-21.2021. This article has 31 citations.](https://doi.org/10.1523/jneurosci.0564-21.2021)

[5. (Hedrich2019SCN2A) Ulrike B. S. Hedrich, Stephan Lauxmann, and Holger Lerche. <scp>scn</scp>2a channelopathies: mechanisms and models. Epilepsia, December 2019. URL: http://dx.doi.org/10.1111/epi.14731, doi:10.1111/epi.14731. This article has 25 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/epi.14731)

[6. (Richardson2021Further) Ruth Richardson, Diana Baralle, Christopher Bennett, Tracy Briggs, Emilia K. Bijlsma, Jill Clayton‐Smith, Panayiotis Constantinou, Nicola Foulds, Joanna Jarvis, Rosalyn Jewell, Diana S. Johnson, Meriel McEntagart, Michael J. Parker, Jessica A. Radley, Lisa Robertson, Claudia Ruivenkamp, Julie W. Rutten, James Tellez, Peter D. Turnpenny, Valerie Wilson, Michael Wright, and Meena Balasubramanian. Further delineation of phenotypic spectrum of <scp>scn2a</scp>‐related disorder. American Journal of Medical Genetics Part A, 188(3):867–877, December 2021. URL: http://dx.doi.org/10.1002/ajmg.a.62595, doi:10.1002/ajmg.a.62595. This article has 5 citations.](https://doi.org/10.1002/ajmg.a.62595)

[7. (Reynolds2020The) Claire Reynolds, Mary D. King, and Kathleen M. Gorman. The phenotypic spectrum of scn2a-related epilepsy. European Journal of Paediatric Neurology, 24:117–122, January 2020. URL: http://dx.doi.org/10.1016/j.ejpn.2019.12.016, doi:10.1016/j.ejpn.2019.12.016. This article has 81 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ejpn.2019.12.016)